Immune Therapeutics, Inc. (OTCMKTS:IMUN) Files An 8-K Other Events
Item 8.01 Other Events
On April 25, 2017, Immune Therapeutics, Inc., a Florida
corporation (the Company) issued a press release announcing that
it has submitted its New Drug Application (NDA) to the Pharmacy
and Poison Board (PPB) in Kenya for LodonalTM, for the
treatment of patients with HIV and cancer, both as a standalone
treatment as well as an adjunct treatment, and as an
immunomodulator. The press release is attached hereto.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. The following exhibits are filed herewith.
| Exhibit No. | Description | |
| 99.1 | Press Release |
About Immune Therapeutics, Inc. (OTCMKTS:IMUN)
Immune Therapeutics, Inc. is a biotechnology company. The Company is involved in the manufacturing, distribution and marketing of therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system using its patented immunotherapy. The Company’s products and immunotherapy technologies are designed to improve the treatment of cancer, infections, such as human immunodeficiency virus (HIV)/acquired immuno deficiency syndrome (AIDS), chronic inflammatory diseases and autoimmune diseases. Its technology platform is built on various immunotherapies, such as Low Dose Naltrexone (LDN) and Methionine-Enkephalin (MENK). Its technology offers treatment for a range of cancers. The Company’s clinical programs involve immunotherapy with Methionine-Enkephalin (MENK) (sometimes referred to as opioid growth factor) and its Low Dose Naltrexone (LDN) product or LodonalTM, which stimulates the immune system even in patients with advanced cancer. Immune Therapeutics, Inc. (OTCMKTS:IMUN) Recent Trading Information
Immune Therapeutics, Inc. (OTCMKTS:IMUN) closed its last trading session down -0.0019 at 0.0680 with 1,544,699 shares trading hands.